10/21/15 - 08:00 AM EDT
The company raised earnings and revenue guidance modestly for the remainder of the year due to the cost savings from the restructuring.
10/20/15 - 11:39 AM EDT
A positive nod from the FDA will prompt Redwood City, Calif-based Relypsa to finalize the hiring of a salesforce and start selling the drug within the next two months.
10/19/15 - 02:51 PM EDT
All of Bluebird's ongoing clinical trials in beta-thalassemia and sickle cell disease use an improved, more potent gene therapy, the company said.
10/16/15 - 10:28 AM EDT
Zafgen is in a tough spot now because the benefit-risk of its lead pipeline drug beloranib is not clear.
10/16/15 - 06:50 AM EDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
10/14/15 - 12:07 PM EDT
No rational company allows its shareholders to suffer extreme losses because of a "no comment" policy on market speculation.
10/14/15 - 11:47 AM EDT
The FDA on Wednesday confirms that Nov. 24 is the date for an advisory committee meeting to review BioMarin's Duchenne drug drisapersen.
10/12/15 - 04:08 PM EDT
The heady days when a biotech company cancelling investor meetings was interpreted as a good thing -- perhaps a sign of a pending takeover -- appear to be over.
10/12/15 - 09:46 AM EDT
Eli Lilly is shutting down clinical development of a cholesterol-lowering pill, removing what could have been the company's next multi-billion-dollar product from its research pipeline.
10/08/15 - 12:10 PM EDT
Advancing the new Vertex drugs into the clinic should also quiet, but not eliminate, investor concerns about competitors closing the gap on the company's market-dominant position in cystic fibrosis treatments.